Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Serotonergic psychedelic: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Unity
Grammatics
>White
design improved
Line 24: Line 24:
===Examples===
===Examples===
<div class='flex-panel'>
<div class='flex-panel'>
    <div class='flex-column'>
<div class='flex-column'>
        <div class="panel radius">
<div class="panel radius">
            <h3 class="panel-header">[[Lysergamide]]s[[File:book.svg|x20px|right|link=]]</h3>
<h3 class="panel-header">[[Lysergamide]]s[[File:book.svg|x20px|right|link=]]</h3>
            <ul class="featured-table">
<ul class="featured-table">
                <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading"></h4>
<h4 class="media-heading"></h4>
* [[1P-LSD]]
* [[1P-LSD]]
Line 38: Line 38:
* [[Lysergic acid diethylamide|LSD]]
* [[Lysergic acid diethylamide|LSD]]
* [[LSZ]]
* [[LSZ]]
                </li>
</li>
 
</div>
        </div>


        <div class="panel radius">
<div class="panel radius">
            <h3 class="panel-header">[[Tryptamine]]s[[File:cogs.svg|x20px|right|link=]]</h3>
<h3 class="panel-header">[[Tryptamine]]s[[File:cogs.svg|x20px|right|link=]]</h3>
 
<ul class="featured-table">
            <ul class="featured-table">
<li class="featured list-item">
                <li class="featured list-item">
<h4 class="media-heading">[[Tryptamine|Base Tryptamines]]</h4>
<h4 class="media-heading">[[Tryptamine|Base Tryptamines]]</h4>
* [[DMT]]
* [[DMT]]
Line 59: Line 57:
* [[PiPT]]
* [[PiPT]]
* [[aMT]]
* [[aMT]]
                </li>
</li>


                <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading">[[Substituted Tryptamine]]s</h4>
<h4 class="media-heading">[[Substituted Tryptamine]]s</h4>
* [[4-PO-DMT]] (''Psilocybin'')
* [[4-PO-DMT]] (''Psilocybin'')
Line 86: Line 84:
* [[5-MeO-DALT]]
* [[5-MeO-DALT]]
* [[5-MeO-MALT]]
* [[5-MeO-MALT]]
                </li>
</li>
</li>
</li>
</div>
</div>


            <p class="panel-footer"> </p>
<div class='flex-column'>
        </div>
<div class="panel radius">
</div>
<h3 class="panel-header">[[Phenethylamine]]s [[File:flask.svg|x20px|right|link=]]</h3>
    <div class='flex-column'>
<ul class="featured-table">
        <div class="panel radius">
<li class="featured list-item">
            <h3 class="panel-header">[[Phenethylamine]]s [[File:flask.svg|x20px|right|link=]]</h3>
            <ul class="featured-table">
                <li class="featured list-item">
* [[Mescaline]]
* [[Mescaline]]
* [[Escaline]]
* [[Escaline]]
Line 103: Line 99:
* [[Methallylescaline]]
* [[Methallylescaline]]
* [[Proscaline]]
* [[Proscaline]]
                </li>
</li>
 
<li class="featured list-item">
                <li class="featured list-item">
<h4 class="media-heading">[[2C-x]] series</h4>
<h4 class="media-heading">[[2C-x]] series</h4>
* [[2C-B]]
* [[2C-B]]
Line 117: Line 112:
* [[2C-T-2]]
* [[2C-T-2]]
* [[2C-T-7]]
* [[2C-T-7]]
                </li>
</li>


                <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading">[[DOx]] series</h4>
<h4 class="media-heading">[[DOx]] series</h4>
* [[DOB]]
* [[DOB]]
Line 127: Line 122:
* [[DOPR]]
* [[DOPR]]
* [[DOM]]
* [[DOM]]
                </li>
</li>


                <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading">[[25x-NBOMe]]s</h4>
<h4 class="media-heading">[[25x-NBOMe]]s</h4>
* [[25B-NBOMe]]
* [[25B-NBOMe]]
Line 136: Line 131:
* [[25I-NBOMe]]
* [[25I-NBOMe]]
* [[25N-NBOMe]]
* [[25N-NBOMe]]
                </li>
</li>


                <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading">Others</h4>
<h4 class="media-heading">Others</h4>
* [[TMA-2]]
* [[TMA-2]]
Line 147: Line 142:
* [[5-MeO-DiBF]]
* [[5-MeO-DiBF]]
* [[Efavirenz]]
* [[Efavirenz]]
</li>
</div>
</div>


                </li>
<div class='flex-column'>
 
<div class="panel radius">
            <p class="panel-footer"> </p>
<h3 class="panel-header">[[Entheogen]]s [[File:users.svg|x20px|right|link=]]</h3>
        </div>
<ul class="featured-table">
 
<li class="featured list-item">
    </div>
    <div class='flex-column'>
        <div class="panel radius">
            <h3 class="panel-header">[[Entheogen]]s [[File:users.svg|x20px|right|link=]]</h3>
 
            <ul class="featured-table">
 
                <li class="featured list-item">
* [[Ayahuasca]]
* [[Ayahuasca]]
* [[Syrian Rue]]
* [[Syrian Rue]]
Line 171: Line 161:
* [[Iboga]]
* [[Iboga]]
* [[Psilocybe Mushroom]]
* [[Psilocybe Mushroom]]
                </li>
</li>


              <li class="featured list-item">
<li class="featured list-item">
<h4 class="media-heading">[[beta-Carboline|β-Carbolines]]</h4>
<h4 class="media-heading">[[beta-Carboline|β-Carbolines]]</h4>
* [[Harmaline]]
* [[Harmaline]]
Line 179: Line 169:
* [[Tetrahydroharmine]]
* [[Tetrahydroharmine]]
</li>
</li>
</div>


        <div class="panel radius">
<div class="panel radius">
            <h3 class="panel-header">Others[[File:cogs.svg|x20px|right|link=]]</h3>
<h3 class="panel-header">Others[[File:cogs.svg|x20px|right|link=]]</h3>
            <ul class="featured-table">
<ul class="featured-table">
                                <li class="featured list-item">
<li class="featured list-item">
* [[Benzydamine]]
* [[Benzydamine]]
* [[Elemicin]]
* [[Elemicin]]
* [[Myristicin]]
* [[Myristicin]]
* [[Mirtazapine]]
* [[Mirtazapine]]
                </li>
</li>
            </ul>
</ul>
            <p class="panel-footer"> </p>
</div>
        </div>
        </div>
[[File:Table.jpg|250px|frameless|right|link=]]
[[File:Table.jpg|250px|frameless|right|link=]]
    </div>
</div>
</div>
</div>



Revision as of 06:36, 10 April 2017

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Psychedelic structural comparison diagram

Serotonergic psychedelics (also known as serotonergic hallucinogens) are a class of hallucinogenic substances with a method of action strongly tied to modifying the normal neurotransmission of serotonin. Serotonin, which is also commonly referred to as 5-HT (from 5-hydroxy-tryptamine) is a naturally-occurring neurotransmitter which is tied to developmental, cardiovascular, gastrointestinal, and endocrine function, sensory perception, behaviors such as aggression, appetite, sex, sleep, mood, cognition, and memory, many of which have yet to be fully understood.[1]

Method of action

The diagram above demonstrates the neural connections associated with sobriety in comparison to being under the influence of psilocybin as demonstrated through the use of MRI scans. The width of the links is proportional to their weight and the size of the nodes is proportional to their strength. Note that the proportion of heavy links between communities is much higher (and very different) in the psilocybin group, suggesting greater integration[2]
Figure 1 - Activation of the prefrontal network and glutamate release by psychedelics. The figure shows a model in which hallucinogens, such as psilocin, lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT), increase extracellular glutamate levels in the prefrontal cortex through stimulation of postsynaptic serotonin (5-hydroxytryptamine) 2A (5-HT 2A ) receptors that are located on large glutamatergic pyramidal cells in deep cortical layers (V and VI) projecting to layer V pyramidal neurons. This glutamate release leads to an activation of AMPA (α-amino-3-hydroxy-5-methyl-4- isoxazole propionic acid) and NMDA (N-methyl-d-aspartate) receptors on cortical pyramidal neurons. in addition, hallucinogens directly activate 5-HT2A receptors located on cortical pyramidal neurons. This activation is thought to ultimately lead to increased expression of brain-derived neurotrophic factor (BDNF).[3]
This image shows how, with eyes-closed, much more of the brain contributes to the visual experience under LSD (right image) than under placebo (left image). The magnitude of this effect correlates with participants’ reports of complex, dreamlike visions.[4]

While the method of action of serotonergic psychedelics is not fully understood, serotonergic psychedelics are known to show affinities for various 5-HT receptors in different ways and levels, and may be classified by their activity at different 5-HT sub-sites, such as 5-HT1A, 5-HT1B, 5-HT2A, etc.

Many serotonergic psychedelics, such as the family of tryptamines, have very strong structural similarities to serotonin itself, which partially explains the affinity for certain 5-HT sites. It is almost unanimously agreed that most serotonergic psychedelics produce their effect by acting as strong partial agonists at the 5-HT2A receptors.

The cortico-striato-thalamo-cortical loops[5] ("CSTC-loops") seem to be central to the function of psychedelics, which are also regulated by the serotonergic system. These control loops connect brain areas like the frontal lobe, the striatum and the thalamus; they aggregate, process and forward internal and external information.

The disruption of the neurotransmitter balance causes these control loops to collapse overwhelmed, leading to the flooding of the frontal lobe with neuronal excitatory glutamate; internal and external stimuli as well as all kinds of non-conscious contents can freely move up to the cerebral cortex and appear as visions in consciousness.[6][7] Furthermore, there is an over-activation of the locus coerlueus and thereby widespread norepinephrine secretion, causing a state of spiritual transcendence and sometimes even intense spiritual experiences.

Worth noting is that selective serotonin reuptake inhibitors (a class of antidepressants including Paxil, Prozac, and Zoloft) can increase the dosage required for hallucinogenic effects of serotonergic psychedelics in some people based on anecdotal reports. Some users, however, have found this to be entirely untrue for them, so users who are using daily antidepressants should, at first, only attempt a common dosage.

Examples

See also

References

  1. David E. Nichols and Charles D. Nichols, Serotonin Receptors. Chemical Reviews. 2008. 108 (5), 1614-1641. https://doi.org/10.1021/cr078224o
  2. Petri, G., Expert, P., Turkheimer, F., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks, 14–18. https://doi.org/10.1038/nrn2618
  3. Vollenweider, F. X., & Kometer, M. (2010). The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders. Nature Publishing Group, 11(9), 642–651. https://doi.org/10.1038/nrn2884
  4. LSD's impact on the brain revealed in groundbreaking images | https://www.theguardian.com/science/2016/apr/11/lsd-impact-brain-revealed-groundbreaking-images
  5. Taylor, S. B., Lewis, C. R., & Olive, M. F. (2013). The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Substance Abuse and Rehabilitation, 4, 29–43. https://doi.org/10.2147/SAR.S39684; [..] The overall output of the basal ganglia is predominantly via the thalamus, which then projects back to the PFC to form cortico-striatal-thalamo-cortical (CSTC) loops. [..]
  6. Vollenweider, F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(4), 265–79. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3181663&tool=pmcentrez&rendertype=abstract
  7. Edelrausch im LaborNeuro Culture Lab (German)